Core Insights - Tilray Medical has achieved a significant milestone in its European expansion by introducing three new medical cannabis flower varieties in Italy, becoming the first company in the country to receive official authorization from the Italian Ministry of Health for the import and distribution of its proprietary medical cannabis products [1][2]. Group 1: Product Launch and Regulatory Approval - The newly approved Tilray Medical products are now available for therapeutic use in pharmacies across Italy, highlighting the company's commitment to providing high-quality, EU-GMP certified medical cannabis [2]. - The authorization from the Italian Ministry of Health underscores the importance of medical cannabis as a therapeutic option for patients, enhancing their health and well-being [2]. Group 2: Company Background and Market Position - Tilray Medical is dedicated to providing safe and reliable access to a global portfolio of medical cannabis brands, having evolved from one of the first licensed producers in Canada to a leading supplier in Europe with EU-GMP certified production facilities in Portugal and Germany [3]. - The company operates in multiple European countries, including Germany, Italy, Portugal, Poland, and the United Kingdom, reinforcing its leadership in the European medical cannabis market [2]. Group 3: Corporate Mission and Vision - Tilray Brands, Inc. aims to be a leading global lifestyle and consumer packaged goods company, focusing on cannabis, wellness, and entertainment, with a mission to inspire joy and create memorable experiences through its diverse portfolio of over 40 brands [5].

Core Insights - Aurora Cannabis Inc. has launched two new proprietary cultivars in Poland, marking the highest potency medical cannabis products available in the country [1][2] - The new products, Farm Gas and Sourdough, are designed to meet the demand for high-quality, high-potency medical cannabis among prescribers and patients [2][3] - Aurora emphasizes its leadership in the international medical cannabis market, leveraging its scientific expertise and understanding of regulatory landscapes [3] Product Details - Farm Gas has a THC content of 27% and less than 1% CBD, with a unique aroma profile featuring notes of kerosene, diesel, and a sweet fruit sherbet finish [7] - Sourdough boasts a THC content of 29% and less than 1% CBD, characterized by sour, cake, and gasoline notes in its aroma profile [7] - Both cultivars are hang-dried and hand-finished, showcasing the company's commitment to quality [2] Company Overview - Aurora Cannabis Inc. operates in the medical and consumer cannabis markets across Canada, Europe, Australia, and New Zealand [4] - The company is known for its diverse brand portfolio, including both medical and adult-use cannabis brands [4] - Aurora holds a controlling interest in Bevo Farms Ltd., a leading supplier of propagated agricultural plants in North America [4]

Core Viewpoint - Apollo Technology Capital Corporation, a significant shareholder of MediPharm Labs Corp., has presented a plan aimed at revitalizing the company and enhancing shareholder value [1][6]. Shareholder Engagement - Shareholders are encouraged to vote for Apollo Capital's six director nominees using the "Gold Card" and to disregard MediPharm's "Green Card" [2][3]. - The communication emphasizes the urgency for shareholders to act in order to protect their investments [2][3]. Ownership and Influence - Apollo Capital, through its subsidiary Nobul Technologies Inc., owns approximately 3% of MediPharm's common shares, totaling 12,491,500 shares [4][6]. - The company is actively seeking to influence the board of directors through its proxy solicitation efforts [11]. Action Plan - Apollo Capital has outlined a commitment to execute an aggressive action plan aimed at increasing MediPharm's share price by over 10 times and preventing insolvency [6]. - The plan includes measures to address excessive executive compensation and rectify three years of value-destructive actions [6]. Legal and Regulatory Compliance - Apollo Capital has filed an amended dissident information circular in compliance with Canadian corporate and securities laws, detailing their director nominees and the rationale behind their actions [5][7]. - Shareholders are advised to read the amended circular carefully as it contains crucial information regarding the upcoming annual meeting [8].

Core Viewpoint - Apollo Capital and Pat McCutcheon emphasize the urgent need for change at MediPharm Lab Corp, advocating for a complete turnover at the board level to restore value for shareholders after years of mismanagement and declining share prices [1][2][5]. Group 1: Management and Governance Issues - MediPharm's share price has significantly collapsed over the past three years, while senior management has received over $10 million in compensation, raising concerns about governance and accountability [2][4]. - The current management has deviated from MediPharm's founding vision by entering the recreational cannabis market and engaging in dilutive mergers and acquisitions, which has not aligned with shareholder interests [2][3]. Group 2: Proposed Changes and Support - Apollo Capital proposes a new board of directors with relevant experience in medical cannabis and turnaround strategies, led by Regan McGee, to drive the company's stock price higher [3][4]. - Shareholders are urged to support Apollo's director nominees by voting the GOLD CARD in the upcoming AGM, as this aligns with the goal of enhancing shareholder value [4][8]. Group 3: Shareholder Engagement - Apollo Capital's business model focuses on investing in poorly managed companies and working with shareholders to secure votes for new governance that prioritizes share value growth [4][5]. - The strategic five-pillar plan for MediPharm has been made available to shareholders, outlining the steps needed to transform the company into a leading player in the medical cannabis sector [7].

TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today issued a Letter to Shareholders from the Company's Board of Directors (the "Letter"). The Letter is a response to the amended and restated dissident proxy circular filed by Apollo on May 20, 2025, and in particular Apollo's plan for the Company. The full text of the Letter to Shareholders follows. MESSAGE FROM THE MEDIPHARM BOA ...

– Acquisitions strengthen profitability and competitive position with proprietary technology platform – – Missouri and Nevada transactions remain on track to close during the second quarter of 2025 – MINNEAPOLIS, May 12, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today announced that it has closed its previously-announced transactions to acquire Utah-based WholesomeCo Cannabis (“Wholesome”) and the Arches proprietary technology and analytics platform. Wh ...

Core Viewpoint - Dogecoin Cash, Inc. has finalized its stock dividend distribution, with a payment date set for May 9, 2025, and the record date remaining November 25, 2024, with no changes to the amount or terms of the dividend [1][3][4]. Group 1: Dividend Details - The stock dividend consists of a new class of preferred stock, where shareholders will receive one share of unrestricted preferred stock for every 1,000 shares of common stock held as of the record date [4]. - The preferred stock, designated as Series A Preferred, allows holders to receive one share of common stock annually per preferred share, contingent upon declaration by the Board of Directors [5]. - The preferred stock is not convertible but can be redeemed at the company's discretion at a rate of ten shares of common stock for each preferred share before October 25, 2034 [5]. Group 2: Company Overview - Dogecoin Cash, Inc. operates in the blockchain innovation sector and owns PrestoDoctor, a leader in medical cannabis telemedicine [7]. - The company holds a patented cannabis strain and a patented cannabis lozenge for hypertension treatment, and is involved in cannabis product development and licensing [7]. - Dogecoin Cash, Inc. is leveraging emerging digital assets and decentralized finance solutions to enhance its offerings and create new market opportunities [7].

MINNEAPOLIS, April 29, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today announced that it will release its financial results for its first fiscal quarter ended March 31, 2025 on Friday, May 9, 2025 before the market opens. Vireo Growth management will host a conference call with the investment community that same day, Friday, May 9, 2025 at 8:30 a.m. ET (7:30 a.m. CT) to discuss its results. Interested parties may attend the conference call by dialing 1- ...

Company Overview - Dogecoin Cash, Inc. has finalized its corporate name change, which is now reflected across U.S. stock market systems following notification from FINRA [1] - The name change was authorized through a Certificate of Amendment filed with the Nevada Secretary of State on November 13, 2024, and became market effective on April 25, 2025 [2] - The trading symbol (CBDS) remains unchanged at this time [3] Business Operations - Dogecoin Cash, Inc. operates PrestoDoctor, a leader in medical cannabis telemedicine [4] - The company holds the first patented cannabis strain, Ecuadorian Sativa aka "CTA", and a patented cannabis lozenge for hypertension treatment [4] - Dogecoin Cash, Inc. is engaged in cannabis product development, licensing, and blockchain innovation, leveraging emerging digital assets and decentralized finance (DeFi) solutions [4]